KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) R&D In Process (2016 - 2026)

Eli Lilly filings provide 17 years of R&D In Process readings, the most recent being $584.0 million for Q1 2026.

  • On a quarterly basis, R&D In Process fell 62.85% to $584.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.9 billion, a 59.46% decrease, with the full-year FY2025 number at $2.9 billion, down 11.28% from a year prior.
  • R&D In Process hit $584.0 million in Q1 2026 for Eli Lilly, up from $530.0 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $3.0 billion in Q3 2023 to a low of $62.4 million in Q3 2022.
  • Median R&D In Process over the past 5 years was $240.1 million (2022), compared with a mean of $676.0 million.
  • The widest YoY moves for R&D In Process: up 4675.64% in 2023, down 77.95% in 2023.
  • Eli Lilly's R&D In Process stood at $240.1 million in 2022, then skyrocketed by 159.39% to $622.8 million in 2023, then tumbled by 69.69% to $188.8 million in 2024, then skyrocketed by 180.72% to $530.0 million in 2025, then increased by 10.19% to $584.0 million in 2026.
  • The last three reported values for R&D In Process were $584.0 million (Q1 2026), $530.0 million (Q4 2025), and $655.7 million (Q3 2025) per Business Quant data.